Jade Biosciences (JBIO) Q2 2026 earnings summary

Executive summary

• Clinical-stage biopharma focused on novel biologics for autoimmune diseases, with three main programs: JADE101 (IgA nephropathy), JADE201 (autoimmune disorders), and JADE301 (dermatomyositis).

• Positive interim Phase 1 results for JADE101 in IgA nephropathy showed strong biomarker activity, durability, and safety, supporting advancement to Phase 2 and planned Phase 3 trials in 2027.

• Dosing began in Phase 1 trial of JADE201 for rheumatoid arthritis; interim data expected in 2027 to inform further development.

• JADE301, a half-life-extended anti-IFN-β antibody for dermatomyositis, is on track for Phase 1 initiation in late 2026, with interim data in 2027.

• No product revenue; operations funded by equity and convertible note offerings.

Financial highlights

• Net loss of $55.8M for Q2 2026, up from $32.1M in Q2 2025; net loss of $96.1M for the six months ended June 30, 2026, up from $70.3M year-over-year.

• Operating expenses rose to $58.9M in Q2 2026 from $27.8M in Q2 2025, driven by increased R&D and G&A costs.

• Cash, cash equivalents, and investments totaled $461.2M as of June 30, 2026, expected to fund operations into Q4 2028.

• Research and development expenses were $50.1M in Q2 2026, up from $22.5M in Q2 2025; G&A expenses were $8.9M, up from $5.2M.

• Total assets increased to $472.1M as of June 30, 2026, from $349.8M at year-end 2025.

Outlook and guidance

• Interim clinical data for JADE101 and JADE201 expected in 2027; Phase 3 trial for JADE101 planned for 1H 2027 pending FDA feedback.

• Interim Phase 1 data for JADE301 anticipated in 2027.

• Cash runway projected into Q4 2028 based on current operating plans.